Viatris Confirms Delay On ‘First And Only’ Botox Biosimilar
Problems For Partner Revance’s Lead Pipeline Candidate Has ‘Direct Impact’
Viatris remains hopeful of obtaining FDA approval for its proposed biosimilar to Botox in partnership with Revance Therapeutics in 2026, after the latter’s manufacturing problems for another drug candidate stymied development of the rival to the world-renowned cosmetic brand.
